Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of pancreatic cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate the biological, clinical and logistical factors that affect the selection of first-line therapy for locally advanced or metastatic pancreatic adenocarcinoma (PAD), and incorporate this information into patient education discussions.
• Assess published efficacy findings with regimens incorporating novel chemotherapeutic formulations as first-line therapy for patients with metastatic PAD, and understand the current role of these approaches.
• Examine available datasets exploring the effect of dose adjustments on the efficacy of chemotherapeutic regimens employed in the management of newly diagnosed metastatic PAD, and consider the potential feasibility of tolerability-guided dosing strategies.
• Recognize FDA-approved treatment approaches for metastatic PAD that has progressed on front-line chemotherapy, and counsel patients regarding the risks and benefits of these strategies.
• Evaluate the mechanism of action of, published research findings with and potential clinical role of tumor treating fields for unresectable, locally advanced PAD.
• Recall relevant oncogenic pathways mediating the pathogenesis of PAD, and discern the implications for biomarker analysis and treatment decision-making.
• Appreciate the spectrum and frequency of RAS mutations found in patients with metastatic PAD, and develop an understanding of available data with and ongoing research studies of novel agents designed to exploit this emerging therapeutic pathway.
• Design and implement a plan of care to recognize and manage side effects and toxicities associated with approved systemic regimens commonly employed in the management of PAD, to support quality of life and continuation of therapy.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Kuhlman and Ms Wagner have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Philip — Advisory Committees: Corcept Therapeutics Inc, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Novocure Inc, Revolution Medicines Inc; Consulting Agreements: Novocure Inc; Contracted Research: Bristol Myers Squibb, Novartis, Revolution Medicines Inc, Taiho Oncology Inc; Data and Safety Monitoring Board/Committees: J-Pharma Co Ltd, Oncolytics Biotech Inc.

MODERATOR — Dr O'Reilly — Advisory Committees and Consulting Agreements (Uncompensated): Agenus Inc, Alligator Bioscience, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Ikena Oncology, Immuneering Corporation, Ipsen Biopharmaceuticals Inc, Merck, MOMA Therapeutics, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Tango Therapeutics; Contracted Research: Agenus Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech SE, Digestive Care Inc, Elicio Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Revolution Medicines Inc, Tango Therapeutics; Nonrelevant Financial Relationships: American Association of Cancer Research (Editor), American Society of Clinical Oncology (Editor), Break Through Cancer, Imedex, National Cancer Institute (Cancer Center Support Grant/Core Grant), National Institutes of Health (research grant), Stand Up 2 Cancer.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.